Nuvation Bio Inc. (NUVB) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth Lose.
17/42
2.0 / 5 stars
All 42 Win/Lose results and 78 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinNUVB / S&P 32.40% / 15.20% |
WinNUVB / S&P 1083.56% / 15.00% |
LoseNUVB / S&P -8.33% / 50.40% |
| 2026-Q11/3 |
LoseNUVB / S&P -52.12% / -4.33% |
WinNUVB / S&P 1205.52% / 11.30% |
LoseNUVB / S&P -80.45% / 27.70% |
| 2025-Q42/3 |
WinNUVB / S&P 142.16% / 2.65% |
WinNUVB / S&P 698.96% / 9.00% |
LoseNUVB / S&P -71.56% / 13.40% |
| 2025-Q32/3 |
WinNUVB / S&P 89.74% / 8.12% |
WinNUVB / S&P 1137.19% / 4.61% |
LoseNUVB / S&P -77.52% / 13.45% |
| 2025-Q21/3 |
LoseNUVB / S&P 10.80% / 10.94% |
WinNUVB / S&P 900.35% / 4.83% |
LoseNUVB / S&P -77.36% / 10.63% |
| 2025-Q11/2 |
LoseNUVB / S&P -33.83% / -4.27% |
No dataNUVB / S&P / 4.98% |
WinNUVB / S&P 587.50% / 10.57% |
| 2024-Q42/2 |
WinNUVB / S&P 16.16% / 2.41% |
No dataNUVB / S&P / 5.25% |
WinNUVB / S&P 502.86% / 6.15% |
| 2024-Q31/2 |
LoseNUVB / S&P -21.58% / 5.89% |
No dataNUVB / S&P / 5.89% |
WinNUVB / S&P 489.19% / 6.11% |
| 2024-Q21/2 |
LoseNUVB / S&P -19.78% / 4.28% |
No dataNUVB / S&P / 5.38% |
WinNUVB / S&P 430.00% / 5.12% |
| 2024-Q11/2 |
WinNUVB / S&P 141.06% / 10.56% |
No dataNUVB / S&P / 5.71% |
LoseNUVB / S&P -31.91% / 5.59% |
| 2023-Q41/2 |
WinNUVB / S&P 12.69% / 11.69% |
No dataNUVB / S&P / 6.81% |
LoseNUVB / S&P -25.53% / 7.78% |
| 2023-Q30/2 |
LoseNUVB / S&P -25.56% / -3.27% |
No dataNUVB / S&P / 7.52% |
LoseNUVB / S&P -26.00% / -5.03% |
| 2023-Q20/2 |
LoseNUVB / S&P 8.43% / 8.74% |
No dataNUVB / S&P / 9.50% |
LoseNUVB / S&P -18.37% / -8.57% |
| 2023-Q11/2 |
LoseNUVB / S&P -13.54% / 7.50% |
No dataNUVB / S&P / 10.77% |
WinNUVB / S&P 11.90% / -15.69% |
| 2022-Q40/1 |
LoseNUVB / S&P -14.29% / 7.56% |
No dataNUVB / S&P / 11.88% |
No dataNUVB / S&P / -17.99% |
| 2022-Q30/1 |
LoseNUVB / S&P -30.86% / -4.88% |
No dataNUVB / S&P / 13.47% |
No dataNUVB / S&P / -1.41% |
| 2022-Q20/1 |
LoseNUVB / S&P -38.40% / -16.10% |
No dataNUVB / S&P / 13.71% |
No dataNUVB / S&P / 11.04% |
| 2022-Q10/1 |
LoseNUVB / S&P -38.12% / -4.60% |
No dataNUVB / S&P / 15.97% |
No dataNUVB / S&P / 42.23% |
| 2021-Q40/1 |
LoseNUVB / S&P -14.49% / 11.03% |
No dataNUVB / S&P / 15.00% |
No dataNUVB / S&P / 96.40% |
| 2021-Q31/1 |
WinNUVB / S&P 6.77% / 0.58% |
No dataNUVB / S&P / 10.77% |
No dataNUVB / S&P / 69.42% |
| 2021-Q20/1 |
LoseNUVB / S&P -10.91% / 8.55% |
No dataNUVB / S&P / 6.58% |
No dataNUVB / S&P / 51.81% |
| 2021-Q10/1 |
LoseNUVB / S&P -10.68% / 6.17% |
No dataNUVB / S&P / -1.06% |
No dataNUVB / S&P / 7.39% |
| 2020-Q40/1 |
LoseNUVB / S&P 4.48% / 12.15% |
No dataNUVB / S&P / -3.72% |
No dataNUVB / S&P / -33.42% |
| 2020-Q30/0 |
No dataNUVB / S&P / 8.93% |
No dataNUVB / S&P / -2.04% |
No dataNUVB / S&P / -27.10% |
| 2020-Q20/0 |
No dataNUVB / S&P / 20.54% |
No dataNUVB / S&P / -0.46% |
No dataNUVB / S&P / -27.11% |
| 2020-Q10/0 |
No dataNUVB / S&P / -19.60% |
No dataNUVB / S&P / 3.47% |
No dataNUVB / S&P / -14.75% |
| 2019-Q40/0 |
No dataNUVB / S&P / 9.07% |
No dataNUVB / S&P / 5.36% |
No dataNUVB / S&P / 2.99% |
| 2019-Q30/0 |
No dataNUVB / S&P / 1.70% |
No dataNUVB / S&P / 5.02% |
No dataNUVB / S&P / 0.21% |
| 2019-Q20/0 |
No dataNUVB / S&P / 4.30% |
No dataNUVB / S&P / 6.64% |
No dataNUVB / S&P / 8.65% |
| 2019-Q10/0 |
No dataNUVB / S&P / 13.65% |
No dataNUVB / S&P / 8.12% |
No dataNUVB / S&P / 14.29% |
| 2018-Q40/0 |
No dataNUVB / S&P / -13.52% |
No dataNUVB / S&P / 9.05% |
No dataNUVB / S&P / 18.23% |
| 2018-Q30/0 |
No dataNUVB / S&P / 7.71% |
No dataNUVB / S&P / 10.21% |
No dataNUVB / S&P / 19.06% |
| 2018-Q20/0 |
No dataNUVB / S&P / 3.43% |
No dataNUVB / S&P / 9.03% |
No dataNUVB / S&P / 14.46% |
| 2018-Q10/0 |
No dataNUVB / S&P / -0.76% |
No dataNUVB / S&P / 7.68% |
No dataNUVB / S&P / 12.46% |
| 2017-Q40/0 |
No dataNUVB / S&P / 6.64% |
No dataNUVB / S&P / 7.03% |
No dataNUVB / S&P / 13.82% |
| 2017-Q30/0 |
No dataNUVB / S&P / 4.48% |
No dataNUVB / S&P / 5.68% |
No dataNUVB / S&P / 17.57% |
| 2017-Q20/0 |
No dataNUVB / S&P / 3.09% |
No dataNUVB / S&P / 4.83% |
No dataNUVB / S&P / 17.74% |
| 2017-Q10/0 |
No dataNUVB / S&P / 6.07% |
No dataNUVB / S&P / 3.67% |
No dataNUVB / S&P / 13.32% |
| 2016-Q40/0 |
No dataNUVB / S&P / 3.82% |
No dataNUVB / S&P / 2.09% |
No dataNUVB / S&P / 7.05% |
| 2016-Q30/0 |
No dataNUVB / S&P / 3.85% |
No dataNUVB / S&P / 0.20% |
No dataNUVB / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | NUVB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 135.35% | 20.78% |
| Annualized return | 135.35% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | NUVB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -25.24% | 83.14% |
| Annualized return | -5.65% | 12.86% |
10Y · 2020-08-26 to 2026-08-27
| Metric | NUVB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -27.94% | 319.30% |
| Annualized return | -3.22% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |